#USA #Veeva Systems #Life Sciences #Pleasanton #AI Agents

Veeva AI Agents to Transform Life Sciences Applications

In a groundbreaking announcement on October 15, 2025, Veeva Systems (NYSE: VEEV) revealed plans to launch its Veeva AI Agents across all applications, starting in December 2025. This innovative suite of AI agents is designed specifically for the life sciences sector, enhancing functionality in crucial areas such as clinical operations, regulatory compliance, safety, quality, medical affairs, and sales. With Veeva AI, the company aims to elevate innovation and productivity in drug development and treatment decision-making.

A Comprehensive Rollout Timeline

The rollout of Veeva AI Agents has been strategically scheduled to address the diverse needs of the life sciences industry:

• - December 2025: Introduction of AI agents for customer relationship management and content management.
• - April 2026: Launch of agents focusing on safety and quality assurance processes.
• - August 2026: Agents to facilitate clinical operations, regulatory affairs, and medical activities will be introduced.
• - December 2026: Final phase to deploy agents for clinical data management.

These agents will leverage advanced large language models (LLMs) developed by leading platforms including Anthropic and Amazon, hosted on Amazon Bedrock. Veeva's AI Agents will have the capability to offer tailored solutions by understanding the context of specific applications while accessing application data, documents, and workflows securely.

Customizability and Scalability

One of the most compelling features of Veeva AI Agents is their customizability. Users can configure and extend the AI agents provided by Veeva according to their specific needs. Furthermore, the ability to create custom agents that draw on either Veeva-hosted models or client-purchased models on cloud platforms like Amazon Bedrock or Microsoft Azure AI Foundry is a significant step towards personalizing the user experience in line with organizational goals.

This scalable utilization model makes it easier for clients to integrate AI functionalities while managing costs efficiently.

A Commitment to Innovation

Veeva's CEO, Peter Gassner, emphasized the transformative potential of AI in the pharmaceutical sector, stating, “AI will fundamentally change how drugs are developed and how treatment decisions are made at the point of care.” This vision highlights Veeva's commitment to enhancing patient access to better medications more quickly by streamlining processes through robust AI tools.

Continuing the Conversation

As the life sciences landscape evolves with technology, Veeva encourages clients to stay informed about the latest developments and features through the Veeva AI Community on Veeva Connect. Here, users can gain insights, share experiences, and explore the full capabilities of Veeva AI.

In conclusion, the impending launch of Veeva AI Agents marks a pivotal moment in the life sciences sector. With their tailored capabilities and scalable options, Veeva is not only addressing current needs but is also paving the way for future innovations that promise to enhance efficiency, safety, and accessibility in healthcare delivery. As the company continues to lead in cloud technology, those in the industry can look forward to a radically improved approach to life sciences applications.

About Veeva Systems

Veeva Systems is a cloud-based software company specializing in the life sciences industry, providing solutions for data management, enterprise consulting, and software development. With a customer base of over 1,500 organizations, including some of the largest biopharmaceutical firms, Veeva is dedicated to driving innovation and product excellence while maintaining the interests of all stakeholders. For more details, visit veeva.com.